Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xizang Weixinkang Pharmaceutical Co Total Current Liabilities Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of ¥365 Mil mean?
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) has a Total Current Liabilities of ¥365 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Xizang Weixinkang Pharmaceutical Co and its competitors.
Is Xizang Weixinkang Pharmaceutical Co's Total Current Liabilities too high?
Xizang Weixinkang Pharmaceutical Co's current Total Current Liabilities is ¥365 Mil. Overall, Xizang Weixinkang Pharmaceutical Co has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Xizang Weixinkang Pharmaceutical Co's Total Current Liabilities compare to ZTS?
Xizang Weixinkang Pharmaceutical Co's Total Current Liabilities of ¥365 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Xizang Weixinkang Pharmaceutical Co and its competitors. Xizang Weixinkang Pharmaceutical Co's current Total Current Liabilities is ¥365 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xizang Weixinkang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co (SHSE:603676) is currently considered Fairly Valued. The stock's GF Value™ is ¥8.93, compared to a current price of ¥8.78 — trading 1.7% below its estimated fair value. The current Total Current Liabilities is ¥365 Mil. Xizang Weixinkang Pharmaceutical Co's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Xizang Weixinkang Pharmaceutical Co (SHSE:603676), the current Total Current Liabilities is ¥365 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Overvalued in 2026?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.78 is trading 1.7% below its estimated GF Value™ of ¥8.93.
GuruFocus considers Xizang Weixinkang Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:603676:
Total Current Liabilities: ¥365 Mil
GF Value™: ¥8.93 vs. price of ¥8.78 (1.7% below fair value)
No single metric tells the full story. See the SHSE:603676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xizang Weixinkang Pharmaceutical Co Business Description
AddressYuanqu South Road, 3rd Floor, Building 4, Industrial Center, No. 5, Zone B, Lhasa Economic and Technological, Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Xizang Weixinkang Pharmaceutical Co Ltd is engaged in research & development, production and sales of chemical pharmaceutical preparations and their raw materials. It also produces and sells liver protection drugs and antibiotic products.
75GF Score
Get the complete analysis for SHSE:603676
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603676 has been successfully added to your 
